OPRYMEA 2.1 mg, extended-release tablet 30 tablets
Active ingredients: Pramipexole dihydrochloride hydrate, Pramipexole
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OPRYMEA 2,1 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) polyamide aluminium polyéthylène de 30 comprimé(s)
- Marketing authorisation holder
- KRKA (SLOVENIE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 30 Jan 2014
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67319215CIP72762292CIP133400927622922Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DICHLORHYDRATE DE PRAMIPEXOLE MONOHYDRATÉcomprimé | 3 mg · un comprimé | SA |
| PRAMIPEXOLEcomprimé | 2,1 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.